Cargando…
Correction: The challenge of COVID-19 and hematopoietic cell transplantation: EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy
Autores principales: | Ljungman, Per, Mikulska, Malgorzata, de la Camara, Rafael, Basak, Grzegorz W., Chabannon, Christian, Corbacioglu, Selim, Duarte, Rafael, Dolstra, Harry, Lankester, Arjan C., Mohty, Mohamad, Montoto, Silvia, Murray, John, de Latour, Régis Peffault, Snowden, John A., Yakoub-Agha, Ibrahim, Verhoeven, Bregje, Kröger, Nicolaus, Styczynski, Jan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278762/ https://www.ncbi.nlm.nih.gov/pubmed/32514158 http://dx.doi.org/10.1038/s41409-020-0965-7 |
Ejemplares similares
-
The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy
por: Ljungman, Per, et al.
Publicado: (2020) -
The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T’s come into focus
por: Passweg, Jakob R., et al.
Publicado: (2020) -
Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years
por: Passweg, Jakob R., et al.
Publicado: (2021) -
Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey
por: Passweg, Jakob R., et al.
Publicado: (2022) -
The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies
por: Passweg, Jakob R., et al.
Publicado: (2019)